Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
XKEM --------Federal Government has approved the sum of $28 million as counterpart commitment for the project.
XKEM --Read Please Win 500%-- Last chance to buy under 0.02 ----- News Reveled -------the next runner-------- Prize target 0.10 -0.25 cents !!!
http://stockcharts.com/def/servlet/SC.web?c=XKEM,uu[m,a]waclyyay[dc][pb50!b200!f][vc60][iut!Ub14!La1...
March 3rd, 2006
Obasanjo to launch locally produced sickle cell drug
President Olusegun Obasanjo President of Nigeria will by June launch NIPRISAN (HEMOXIN(TM)), the locally produced drug for sickle cell disorder.
PATIENCE OGBE Abuja
The president will also use the occasion to commission Xechem International Inc. factory in the country in a move seen as a landmark investment in Nigeria. The company owns the exclusive rights to NIPRISAN
The drug NIPRISAN (HEMOXIN(TM), which is at present, undergoing final stage of registration with NAFDAC is a phyto-pharmaceutical drug for the treatment of patients suffering from Sickle Cell Disease (SCD). SCD is an insidious and painful genetic blood disorder often resulting in death at an early age.
Science and Technology Minister, Turner Isoun who disclosed this in Abuja noted that location of the factory in Nigeria would further crash the price of sickle cell drugs in Nigeria.
Isoun stated that Niprisan (HEMOXIN(TM)) was a drug cocktail, with phyto-pharmaceutical composition of four traditional plants extracted in a proprietary process. The licensor of the technology is the National Institute for Pharmaceutical Research and Development (NIPRD) in Abuja, Nigeria.
Nigeria is said to have the highest sickle cell disease population in the world ranging from four to six million representing roughly three to five percent of the country's population.
Isoun spoke at the inaugural meeting of the Ministers’ Council for the National Biotechnology Development Agency (NABDA) where he also called on the government to involve more laboratories for the control and analysis of the bird flu menace.
On the situation of bio technology in Nigeria, he called on the stockholding agencies to ensure that Nigeria benefits from the judicious and safe use of modern biotechnology.
"Biotech is a gold mine and important to this nation. Almost every Nigerian is affected by the operations of biotech. To be able to achieve all these, we will require the concerted political will and a focused leadership drive. It is therefore the collective responsibility of all of us key stakeholders of modern biotechnology to join forces in realizing this vision.
It is my belief that this collective mission will not jeopardize our separate mandates but will promote the effective coordination of our effort towards achieving the same ultimate goal."
To achieve the nation’s targets in biotech, the Director General of the National Biotechnology Development Agency (NABDA), Bamidele Solomon called for the establishment of biotechnology development fund.
The fund, he stressed, could help the nation support competent researches and be ready to tackle problems like the bird flu.
He also disclosed that Nigeria in collaboration with Trinity Biotech of the Republic of Ireland will establish a facility at SHESTCO Abuja for the production of test kits for HIV/AIDS and other diseases like HB, malaria and so on.
He added that the Federal Government has approved the sum of $28 million as counterpart commitment for the project.
He also spoke of Nigeria’s collaboration with Shantha Biotechnics Limited of India for the establishment a facility for the production of Hepatitis B vaccine and other vaccines for related diseases like typhoid, polio, DTP and related ailments.
"Government approved the sum of N10 Million in the 2004 capital budget to support carrying out of a detailed feasibility study and fulfilling other MoU requirement."
More In Headlines
» NAICOM introduces new Viser
» How big are Nigerian Banks?
» PlatinumHabib Bank now Bank PHB
» A celebration of African...
» Asian firm to invest $5bn in...
» pic030306
» Nigeria loses $25billion...
This words are the key !!!! In march they start ! Read carefully!
This is a historic day for Xechem International and its lead product NICOSAN(TM)/HEMOXIN(TM). We are extremely excited about our strategic alliance with Alembic, a well-established pharmaceutical company in India. Alembic's financial, technical and distribution strength will accelerate our ability to successfully launch NICOSAN(TM)/HEMOXIN(TM) first in Nigeria and surrounding countries where such conditions are a national priority, followed by the USA, Europe, Latin America, and Asian countries. Alembic's faith in Xechem and its technology validates our excitement about the product, and our immediate opportunity in Africa. We believe this will accelerate our drive toward clinical trials of NICOSAN(TM)/HEMOXIN(TM) in the United States."
---------------------------------
Brings words and photos together (easily) with
PhotoMail - it's free and works with Yahoo! Mail.
[Non-text portions of this message have been removed]
SPONSORED LINKS
Business finance schools Business finance online Business finance course Small business finance Business finance class
---------------------------------
YAHOO! GROUPS LINKS
Visit your group "adaytradersdream" on the web.
To unsubscribe from this group, send an email to:
adaytradersdream-unsubscribe@yahoogroups.com
Your use of Yahoo! Groups is subject to the Yahoo! Terms of Service.
---------------------------------
charles wilson <profitablestock@yahoo.com> escribió: UPDA Projects 4th Quarter Revenue Of Subsidiaries - Should Approach Or Exceed $5 Million Per Month(a)
Tuesday October 25, 8:23 am ET JUNO BEACH, Fla.--(BUSINESS WIRE)--Oct. 25, 2005--The management of Universal Property Development and Acquisition Corporation (OTCBB:UPDA - News) has completed the refinement of its business model in order to focus on oil and natural gas development and finalized its strategic planning and revenue forecasting for Canyon Creek Oil and Gas, Inc., its Texas subsidiary, and West Oil and Gas, Inc., its subsidiary in Utah. ADVERTISEMENT
if (window.yzq_a == null) document.write(""); if (window.yzq_a) { yzq_a('p', 'P=Gq4ZPESOxCbexr7mQ870sgJoyGoDjEPRFH4ADXoh&T=1cugfak5b%2fX%3d1137775743%2fE%3d7811759%2fR%3dfin%2fK%3d5%2fV%3d1.1%2fW%3d8%2fY%3dYAHOO%2fF%3d1357095360%2fH%3dY29icmFuZD0iPGEgaHJlZj1odHRwOi8vd3d3LmJ1c2luZXNzd2lyZS5jb20.PGltZyBib3JkZXI9MCBzcmM9aHR0cDovL3VzLmkxLnlpbWcuY29tL3VzLnlpbWcuY29tL2kvdXMvZmkvZ3IvcGFydG5lcl9sb2dvcy9idXNpbmVzc3dpcmVfMTcweDMzX2xvZ28uZ2lmIGFsdD1CdXNpbmVzc1dpcmUuY29tPjwvYT4iIGNhY2hlaGludD0iNzgxMTc1OSIgY2FjaGVoaW50PSI3ODExNzU5Ig--%2fS%3d1%2fJ%3dB9C28E44'); yzq_a('a', '&U=139qkqlpp%2fN%3dwabpJ0SOxJA-%2fC%3d344566.7748030.8603301.1383221%2fD%3dLREC%2fB%3d3218353'); } After meeting with the management of those subsidiaries over the course of the past month, UPDA is prepared to project the subsidiaries will generate gross revenues approaching or exceeding $5 million per month by the end of the 4th Quarter of 2005(a). Since July, Canyon Creek, a joint venture with USProduction and
Exploration, LLC. (USPX), has acquired seven oil and gas fields totalling over 3200 acres. It is performing a revitalization project in 5 of the fields and will have wells in each field in production this quarter. Conservative production estimates for the wells that will be brought on line this quarter indicate that Canyon Creek will produce approximately 100,000 mcf of natural gas(a) and more than 4250 barrels of oil per month(a). Conservatively assuming gas prices of $10.00/mcf and oil prices of $60.00/barrel, Canyon Creek will be generating nearly $1.4 million per month of gross revenue(a). UPDA has recently agreed to increase its stake in Canyon Creek to 65%. In October, UPDA entered into a joint venture with Dark Horse Exploration, Inc. and Masaood Group, USA and established West Oil & Gas, Inc. in order to develop the 4000 acre Dirty Devil Gas Field in Uintah County, Utah. Two wells are presently generating about 4500 mcfg per day. Three additional wells will be brought on
line during this quarter, increasing conservative production estimates to nearly 320,000 mcfg per month(a). Should natural gas prices continue to increase as anticipated, West will generate as much as $3.5 million per month or more by the end of the 4th quarter(a). UPDA owns 60% of West.
---------------------------------
What are the most popular cars? Find out at Yahoo! Autos
[Non-text portions of this message have been removed]
---------------------------------
YAHOO! GROUPS LINKS
Visit your group "superpicks" on the web.
To unsubscribe from this group, send an email to:
superpicks-unsubscribe@yahoogroups.com
Your use of Yahoo! Groups is subject to the Yahoo! Terms of Service.
---------------------------------
[Non-text portions of this message have been removed]
--------------------------------------------------------------------------------
YAHOO! GROUPS LINKS
Visit your group "forex_inside_trader" on the web.
To unsubscribe from this group, send an email to:
forex_inside_trader-unsubscribe@yahoogroups.com
Your use of Yahoo! Groups is subject to the Yahoo! Terms of Service.
--------------------------------------------------------------------------------
We complete the puzzle !
OK , WELL O,O3 - 0.035 NEXT WEEK!!!!!
XKEM--------By: gaycrisis
03 Mar 2006, 08:17 PM EST
Msg. 8073 of 8094
Jump to msg. #
attention: XKEM just emailed me look:
From : Steve Burg
Sent : Friday, March 3, 2006 4:31 PM
To : XXXX
Dear XXXX
Thank you for your inquiry regarding our Nicosan product in Nigeria.
We have submitted final documents to the government (NAFDAC) and are awaiting approval of our plant and the drug.
As soon as we receive that approval, we will begin selling Nicosan in Nigeria.
Steve Burg
Office: 707-425-8855
Cell: 707-326-9956
Fax: 707-421-1288
XKEM--------By: gaycrisis
03 Mar 2006, 08:17 PM EST
Msg. 8073 of 8094
Jump to msg. #
attention: XKEM just emailed me look:
From : Steve Burg
Sent : Friday, March 3, 2006 4:31 PM
To : XXXX
Dear XXXX
Thank you for your inquiry regarding our Nicosan product in Nigeria.
We have submitted final documents to the government (NAFDAC) and are awaiting approval of our plant and the drug.
As soon as we receive that approval, we will begin selling Nicosan in Nigeria.
Steve Burg
Office: 707-425-8855
Cell: 707-326-9956
Fax: 707-421-1288
XKEM--------By: gaycrisis
03 Mar 2006, 08:17 PM EST
Msg. 8073 of 8094
Jump to msg. #
attention: XKEM just emailed me look:
From : Steve Burg
Sent : Friday, March 3, 2006 4:31 PM
To : XXXX
Dear XXXX
Thank you for your inquiry regarding our Nicosan product in Nigeria.
We have submitted final documents to the government (NAFDAC) and are awaiting approval of our plant and the drug.
As soon as we receive that approval, we will begin selling Nicosan in Nigeria.
Steve Burg
Office: 707-425-8855
Cell: 707-326-9956
Fax: 707-421-1288
XKEM--------By: gaycrisis
03 Mar 2006, 08:17 PM EST
Msg. 8073 of 8094
Jump to msg. #
attention: XKEM just emailed me look:
From : Steve Burg
Sent : Friday, March 3, 2006 4:31 PM
To : XXXX
Dear XXXX
Thank you for your inquiry regarding our Nicosan product in Nigeria.
We have submitted final documents to the government (NAFDAC) and are awaiting approval of our plant and the drug.
As soon as we receive that approval, we will begin selling Nicosan in Nigeria.
Steve Burg
Office: 707-425-8855
Cell: 707-326-9956
Fax: 707-421-1288
Xkem ready to run !
XKEM 0.05 !!!!
XKEm ----- amazing chart !
XKEM-------"The president of nigeria will also use the occasion to commission Xechem International Inc. factory in the country in a move seen as a landmark investment in Nigeria. The company owns the exclusive rights to NIPRISAN"
This is a great news for XKEm shareholders ---- iwill see 0.10 cents soon !
XKEM-------"The president of nigeria will also use the occasion to commission Xechem International Inc. factory in the country in a move seen as a landmark investment in Nigeria. The company owns the exclusive rights to NIPRISAN"
This is a great news for XKEm shareholders ---- iwill see 0.10 cents soon !
XKEM-------"The president of nigeria will also use the occasion to commission Xechem International Inc. factory in the country in a move seen as a landmark investment in Nigeria. The company owns the exclusive rights to NIPRISAN"
This is a great news for XKEm shareholders ---- iwill see 0.10 cents soon !
XKEM-------"The president of nigeria will also use the occasion to commission Xechem International Inc. factory in the country in a move seen as a landmark investment in Nigeria. The company owns the exclusive rights to NIPRISAN"
This is a great news for XKEm shareholders ---- iwill see 0.10 cents soon !
XKEM-------"The president of nigeria will also use the occasion to commission Xechem International Inc. factory in the country in a move seen as a landmark investment in Nigeria. The company owns the exclusive rights to NIPRISAN"
This is a great news for XKEm shareholders ---- iwill see 0.10 cents soon !
XKEM news>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>
http://www.businessdayonline.com/?c=44&a=4926
tks for your attention !
XKEM --------March 3rd, 2006
Obasanjo President of NIGERIA to launch locally produced sickle cell drug
President Olusegun Obasanjo President of NIGERIA will by June launch NIPRISAN (HEMOXIN(TM)), the locally produced drug for sickle cell disorder.
PATIENCE OGBE Abuja
The president will also use the occasion to commission Xechem International Inc. factory in the country in a move seen as a landmark investment in Nigeria. The company owns the exclusive rights to NIPRISAN
The drug NIPRISAN (HEMOXIN(TM), which is at present, undergoing final stage of registration with NAFDAC is a phyto-pharmaceutical drug for the treatment of patients suffering from Sickle Cell Disease (SCD). SCD is an insidious and painful genetic blood disorder often resulting in death at an early age.
Science and Technology Minister, Turner Isoun who disclosed this in Abuja noted that location of the factory in Nigeria would further crash the price of sickle cell drugs in Nigeria.
Isoun stated that Niprisan (HEMOXIN(TM)) was a drug cocktail, with phyto-pharmaceutical composition of four traditional plants extracted in a proprietary process. The licensor of the technology is the National Institute for Pharmaceutical Research and Development (NIPRD) in Abuja, Nigeria.
Nigeria is said to have the highest sickle cell disease population in the world ranging from four to six million representing roughly three to five percent of the country's population.
Isoun spoke at the inaugural meeting of the Ministers’ Council for the National Biotechnology Development Agency (NABDA) where he also called on the government to involve more laboratories for the control and analysis of the bird flu menace.
On the situation of bio technology in Nigeria, he called on the stockholding agencies to ensure that Nigeria benefits from the judicious and safe use of modern biotechnology.
"Biotech is a gold mine and important to this nation. Almost every Nigerian is affected by the operations of biotech. To be able to achieve all these, we will require the concerted political will and a focused leadership drive. It is therefore the collective responsibility of all of us key stakeholders of modern biotechnology to join forces in realizing this vision.
It is my belief that this collective mission will not jeopardize our separate mandates but will promote the effective coordination of our effort towards achieving the same ultimate goal."
To achieve the nation’s targets in biotech, the Director General of the National Biotechnology Development Agency (NABDA), Bamidele Solomon called for the establishment of biotechnology development fund.
The fund, he stressed, could help the nation support competent researches and be ready to tackle problems like the bird flu.
He also disclosed that Nigeria in collaboration with Trinity Biotech of the Republic of Ireland will establish a facility at SHESTCO Abuja for the production of test kits for HIV/AIDS and other diseases like HB, malaria and so on.
He added that the Federal Government has approved the sum of $28 million as counterpart commitment for the project.
He also spoke of Nigeria’s collaboration with Shantha Biotechnics Limited of India for the establishment a facility for the production of Hepatitis B vaccine and other vaccines for related diseases like typhoid, polio, DTP and related ailments.
"Government approved the sum of N10 Million in the 2004 capital budget to support carrying out of a detailed feasibility study and fulfilling other MoU requirement."
More In Headlines
» NAICOM introduces new Viser
» How big are Nigerian Banks?
» PlatinumHabib Bank now Bank PHB
» A celebration of African...
» Asian firm to invest $5bn in...
» pic030306
» Nigeria loses $25billion...
--
XKEM --------March 3rd, 2006
Obasanjo President of NIGERIA to launch locally produced sickle cell drug
President Olusegun Obasanjo President of NIGERIA will by June launch NIPRISAN (HEMOXIN(TM)), the locally produced drug for sickle cell disorder.
PATIENCE OGBE Abuja
The president will also use the occasion to commission Xechem International Inc. factory in the country in a move seen as a landmark investment in Nigeria. The company owns the exclusive rights to NIPRISAN
The drug NIPRISAN (HEMOXIN(TM), which is at present, undergoing final stage of registration with NAFDAC is a phyto-pharmaceutical drug for the treatment of patients suffering from Sickle Cell Disease (SCD). SCD is an insidious and painful genetic blood disorder often resulting in death at an early age.
Science and Technology Minister, Turner Isoun who disclosed this in Abuja noted that location of the factory in Nigeria would further crash the price of sickle cell drugs in Nigeria.
Isoun stated that Niprisan (HEMOXIN(TM)) was a drug cocktail, with phyto-pharmaceutical composition of four traditional plants extracted in a proprietary process. The licensor of the technology is the National Institute for Pharmaceutical Research and Development (NIPRD) in Abuja, Nigeria.
Nigeria is said to have the highest sickle cell disease population in the world ranging from four to six million representing roughly three to five percent of the country's population.
Isoun spoke at the inaugural meeting of the Ministers’ Council for the National Biotechnology Development Agency (NABDA) where he also called on the government to involve more laboratories for the control and analysis of the bird flu menace.
On the situation of bio technology in Nigeria, he called on the stockholding agencies to ensure that Nigeria benefits from the judicious and safe use of modern biotechnology.
"Biotech is a gold mine and important to this nation. Almost every Nigerian is affected by the operations of biotech. To be able to achieve all these, we will require the concerted political will and a focused leadership drive. It is therefore the collective responsibility of all of us key stakeholders of modern biotechnology to join forces in realizing this vision.
It is my belief that this collective mission will not jeopardize our separate mandates but will promote the effective coordination of our effort towards achieving the same ultimate goal."
To achieve the nation’s targets in biotech, the Director General of the National Biotechnology Development Agency (NABDA), Bamidele Solomon called for the establishment of biotechnology development fund.
The fund, he stressed, could help the nation support competent researches and be ready to tackle problems like the bird flu.
He also disclosed that Nigeria in collaboration with Trinity Biotech of the Republic of Ireland will establish a facility at SHESTCO Abuja for the production of test kits for HIV/AIDS and other diseases like HB, malaria and so on.
He added that the Federal Government has approved the sum of $28 million as counterpart commitment for the project.
He also spoke of Nigeria’s collaboration with Shantha Biotechnics Limited of India for the establishment a facility for the production of Hepatitis B vaccine and other vaccines for related diseases like typhoid, polio, DTP and related ailments.
"Government approved the sum of N10 Million in the 2004 capital budget to support carrying out of a detailed feasibility study and fulfilling other MoU requirement."
More In Headlines
» NAICOM introduces new Viser
» How big are Nigerian Banks?
» PlatinumHabib Bank now Bank PHB
» A celebration of African...
» Asian firm to invest $5bn in...
» pic030306
» Nigeria loses $25billion...
--
XKEM --------March 3rd, 2006
Obasanjo to launch locally produced sickle cell drug
E-MAIL THIS PRINT THIS
President Olusegun Obasanjo will by June launch NIPRISAN (HEMOXIN(TM)), the locally produced drug for sickle cell disorder.
PATIENCE OGBE Abuja
The president will also use the occasion to commission Xechem International Inc. factory in the country in a move seen as a landmark investment in Nigeria. The company owns the exclusive rights to NIPRISAN
The drug NIPRISAN (HEMOXIN(TM), which is at present, undergoing final stage of registration with NAFDAC is a phyto-pharmaceutical drug for the treatment of patients suffering from Sickle Cell Disease (SCD). SCD is an insidious and painful genetic blood disorder often resulting in death at an early age.
Science and Technology Minister, Turner Isoun who disclosed this in Abuja noted that location of the factory in Nigeria would further crash the price of sickle cell drugs in Nigeria.
Isoun stated that Niprisan (HEMOXIN(TM)) was a drug cocktail, with phyto-pharmaceutical composition of four traditional plants extracted in a proprietary process. The licensor of the technology is the National Institute for Pharmaceutical Research and Development (NIPRD) in Abuja, Nigeria.
Nigeria is said to have the highest sickle cell disease population in the world ranging from four to six million representing roughly three to five percent of the country's population.
Isoun spoke at the inaugural meeting of the Ministers’ Council for the National Biotechnology Development Agency (NABDA) where he also called on the government to involve more laboratories for the control and analysis of the bird flu menace.
On the situation of bio technology in Nigeria, he called on the stockholding agencies to ensure that Nigeria benefits from the judicious and safe use of modern biotechnology.
"Biotech is a gold mine and important to this nation. Almost every Nigerian is affected by the operations of biotech. To be able to achieve all these, we will require the concerted political will and a focused leadership drive. It is therefore the collective responsibility of all of us key stakeholders of modern biotechnology to join forces in realizing this vision.
It is my belief that this collective mission will not jeopardize our separate mandates but will promote the effective coordination of our effort towards achieving the same ultimate goal."
To achieve the nation’s targets in biotech, the Director General of the National Biotechnology Development Agency (NABDA), Bamidele Solomon called for the establishment of biotechnology development fund.
The fund, he stressed, could help the nation support competent researches and be ready to tackle problems like the bird flu.
He also disclosed that Nigeria in collaboration with Trinity Biotech of the Republic of Ireland will establish a facility at SHESTCO Abuja for the production of test kits for HIV/AIDS and other diseases like HB, malaria and so on.
He added that the Federal Government has approved the sum of $28 million as counterpart commitment for the project.
He also spoke of Nigeria’s collaboration with Shantha Biotechnics Limited of India for the establishment a facility for the production of Hepatitis B vaccine and other vaccines for related diseases like typhoid, polio, DTP and related ailments.
"Government approved the sum of N10 Million in the 2004 capital budget to support carrying out of a detailed feasibility study and fulfilling other MoU requirement."
More In Headlines
» NAICOM introduces new Viser
» How big are Nigerian Banks?
» PlatinumHabib Bank now Bank PHB
» A celebration of African...
» Asian firm to invest $5bn in...
» pic030306
» Nigeria loses $25billion...
--
XKEM --------March 3rd, 2006
Obasanjo to launch locally produced sickle cell drug
E-MAIL THIS PRINT THIS
President Olusegun Obasanjo will by June launch NIPRISAN (HEMOXIN(TM)), the locally produced drug for sickle cell disorder.
PATIENCE OGBE Abuja
The president will also use the occasion to commission Xechem International Inc. factory in the country in a move seen as a landmark investment in Nigeria. The company owns the exclusive rights to NIPRISAN
The drug NIPRISAN (HEMOXIN(TM), which is at present, undergoing final stage of registration with NAFDAC is a phyto-pharmaceutical drug for the treatment of patients suffering from Sickle Cell Disease (SCD). SCD is an insidious and painful genetic blood disorder often resulting in death at an early age.
Science and Technology Minister, Turner Isoun who disclosed this in Abuja noted that location of the factory in Nigeria would further crash the price of sickle cell drugs in Nigeria.
Isoun stated that Niprisan (HEMOXIN(TM)) was a drug cocktail, with phyto-pharmaceutical composition of four traditional plants extracted in a proprietary process. The licensor of the technology is the National Institute for Pharmaceutical Research and Development (NIPRD) in Abuja, Nigeria.
Nigeria is said to have the highest sickle cell disease population in the world ranging from four to six million representing roughly three to five percent of the country's population.
Isoun spoke at the inaugural meeting of the Ministers’ Council for the National Biotechnology Development Agency (NABDA) where he also called on the government to involve more laboratories for the control and analysis of the bird flu menace.
On the situation of bio technology in Nigeria, he called on the stockholding agencies to ensure that Nigeria benefits from the judicious and safe use of modern biotechnology.
"Biotech is a gold mine and important to this nation. Almost every Nigerian is affected by the operations of biotech. To be able to achieve all these, we will require the concerted political will and a focused leadership drive. It is therefore the collective responsibility of all of us key stakeholders of modern biotechnology to join forces in realizing this vision.
It is my belief that this collective mission will not jeopardize our separate mandates but will promote the effective coordination of our effort towards achieving the same ultimate goal."
To achieve the nation’s targets in biotech, the Director General of the National Biotechnology Development Agency (NABDA), Bamidele Solomon called for the establishment of biotechnology development fund.
The fund, he stressed, could help the nation support competent researches and be ready to tackle problems like the bird flu.
He also disclosed that Nigeria in collaboration with Trinity Biotech of the Republic of Ireland will establish a facility at SHESTCO Abuja for the production of test kits for HIV/AIDS and other diseases like HB, malaria and so on.
He added that the Federal Government has approved the sum of $28 million as counterpart commitment for the project.
He also spoke of Nigeria’s collaboration with Shantha Biotechnics Limited of India for the establishment a facility for the production of Hepatitis B vaccine and other vaccines for related diseases like typhoid, polio, DTP and related ailments.
"Government approved the sum of N10 Million in the 2004 capital budget to support carrying out of a detailed feasibility study and fulfilling other MoU requirement."
More In Headlines
» NAICOM introduces new Viser
» How big are Nigerian Banks?
» PlatinumHabib Bank now Bank PHB
» A celebration of African...
» Asian firm to invest $5bn in...
» pic030306
» Nigeria loses $25billion...
--
xkem ''' dont loosee this incredible oportunity !!!!!XKEM ------- NEWS OUT ! Ready to 0.15 cents!
HOT NEWS!!! http://www.businessdayonline.com/?c=44&a=4926
http://www.businessdayonline.com/?c=44&a=4926
Xkem '''''' this a real company ! look news an win 1000%
XKEM ------- NEWS OUT ! Ready to 0.15 cents!
HOT NEWS!!! http://www.businessdayonline.com/?c=44&a=4926
http://www.businessdayonline.com/?c=44&a=4926
this news next week in otc !
XKEM ------- NEWS OUT ! Ready to 0.15 cents!
HOT NEWS!!! http://www.businessdayonline.com/?c=44&a=4926
http://www.businessdayonline.com/?c=44&a=4926
XKEM ------- NEWS OUT ! Ready to 0.15 cents!
HOT NEWS!!! http://www.businessdayonline.com/?c=44&a=4926
http://www.businessdayonline.com/?c=44&a=4926
XKEM ------- NEWS OUT ! Ready to 0.15 cents!
HOT NEWS!!! http://www.businessdayonline.com/?c=44&a=4926
http://www.businessdayonline.com/?c=44&a=4926
XKEM ------- NEWS OUT ! Ready to 0.15 cents!
HOT NEWS!!! http://www.businessdayonline.com/?c=44&a=4926
http://www.businessdayonline.com/?c=44&a=4926
XKEM ------- NEWS OUT ! Ready to 0.15 cents!
HOT NEWS!!! http://www.businessdayonline.com/?c=44&a=4926
http://www.businessdayonline.com/?c=44&a=4926
XKEM ------- NEWS OUT ! Ready to 0.15 cents!
HOT NEWS!!! http://www.businessdayonline.com/?c=44&a=4926
http://www.businessdayonline.com/?c=44&a=4926
XKEM ------- NEWS OUT ! Ready !
HOT NEWS!!! http://www.businessdayonline.com/?c=44&a=4926
http://www.businessdayonline.com/?c=44&a=4926
Good oportunity to pick under 0.0120 !
look chart , this ready to explode !
XKEm -------------Something BIG HERE !!!!!
ALEMBIC new Owner a 100 years company !!!!!!!
This is a historic day for Xechem International and its lead product NICOSAN(TM)/HEMOXIN(TM). We are extremely excited about our strategic alliance with Alembic, a well-established pharmaceutical company in India. Alembic's financial, technical and distribution strength will accelerate our ability to successfully launch NICOSAN(TM)/HEMOXIN(TM) first in Nigeria and surrounding countries where such conditions are a national priority, followed by the USA, Europe, Latin America, and Asian countries. Alembic's faith in Xechem and its technology validates our excitement about the product, and our immediate opportunity in Africa. We believe this will accelerate our drive toward clinical trials of NICOSAN(TM)/HEMOXIN(TM) in the United States."
Food and Drug Administration (FDA) in the USA has granted the orphan drug status to HEMOXIN(TM), and when appropriate FDA regulatory approval is attained, after the US clinical trials, the sales will start immediately. Xechem has agreed to use its best efforts to provide a board seat to designee from Alembic, subject to Alembic's fulfillment of its obligations.
The European Medicine Evaluation Agency has approved orphan drug status for the phytomedicine niprisan in the treatment of sickle cell disease; Germany's Federal Institute for Drugs and Devices has approved modafinil tablets for the treatment of moderate to severe chronic shift work sleep disorder; and Costa Rica's Ministry of Health has approved a hyaluronic acid–based gel for the management of exuding or debrided wounds.
Orphan Drug Niprisan (Nicosan/Hemoxin) for Sickle Cell Disease in EU
The European Medicine Evaluation Agency (EMEA) approved orphan drug status for the phytomedicine niprisan (Nicosan/Hemoxin, made by Xechem International, Inc.) for the treatment of sickle cell disease (SCD).
Niprisan is an ethanol/water extract of Piper guineenses seeds, Pterocapus osum stem, Eugenia caryophyllum fruit, and Sorghum bicolor leaves.
The approval was based in part on data from a phase 2b, placebo-controlled, double-blind crossover study in 82 Nigerian patients. The data showed that treatment with niprisan significantly reduced the frequency of SCD crises associated with severe pain during a six-month period (P < .01). Moreover, 73% of patients achieved complete remission.
Niprisan did not appear to cause acute hepatic toxicity, as assessed by liver enzyme activity; evaluation of serum creatinine and blood urea nitrogen levels suggested that renal function also remained normal. No serious adverse events were reported.
Niprisan (Hemoxin) was previously granted orphan drug status for this indication by the U.S. Food and Drug Administration in March 2006.
Modafinil (Vigil) to Treat Chronic Shift Work Sleep Disorder in Germany
The Germany's Federal Institute for Drugs and Devices approved modafinil (Vigil tablets, made by Cephalon, Inc.) for the treatment of moderate to severe chronic shift work sleep disorder with excessive sleepiness in patients working night shifts who have not responded adequately to sleep hygiene measures.
The approval was based on data from a double-blind, 12-week study in 209 patients showing that nightly treatment with 200 mg of modafinil increased sleep latency from baseline (1.7 ± 0.4 vs 0.3 ± 0.3 minutes; P = .002) and improved clinical symptoms in a greater proportion of patients (74% vs 36%; P < .001) compared with placebo.
Modafinil-treated patients also experienced a decrease from baseline in the frequency and duration of attention lapses during nighttime testing, contrasting with the increase observed among those receiving placebo (Psychomotor Vigilance Test score, –2.6 vs 3.8; P < .001).
In addition, patients receiving modafinil therapy reported fewer accidents or near misses while driving home from work compared with those receiving placebo (29% vs 54%; P < .001).
The most commonly reported adverse events associated with modafinil therapy were headache (25%) and nausea (9%). Treatment did not adversely affect daytime sleep compared with placebo.
Although 200 mg of modafinil reduced the extreme sleepiness of chronic shift work sleep disorder and resulted in small but significant improvements in performance compared with placebo, patients continued to have residual sleepiness and impaired performance at night. This finding suggests that the therapy is not completely effective and underscores the need for development of more effective interventions.
Modafinil tablets were previously approved for this indication by the U.K. Medicines and Healthcare Products Regulatory Agency and the U.S. Food and Drug Administration (FDA).
Other approved indications for modafinil in Germany include narcolepsy and moderately severe to severe obstructive sleep apnea with excessive daytime sleepiness despite nocturnal continuous positive airway pressure. Modafinil tablets are also approved by the FDA to improve wakefulness in patients with excessive sleepiness associated with narcolepsy and obstructive sleep apnea/hypopnea syndrome.
Hyaluronic Acid Gel (IPM Wound Gel) for Healing Ulcers and Debrided Wounds in Costa Rica
The Republic of Costa Rica's Ministry of Health approved a hyaluronic acid (HA)–based gel (IPM Wound Gel, made by LAM Pharmaceutical Corp. and distributed by aQva Pharmaceuticals, Inc.) for the management of exuding (such as leg, pressure, and diabetic ulcers) and debrided wounds. The product is also available without a prescription for use on minor abrasions and cuts.
The clear and odorless aqueous gel is composed mainly of sodium hyaluronate, a purified derivative salt of HA obtained from avian sources. Unlike other glycosaminoglycans such as chondroitin or chondroitin sulfate, HA is not immunogenic.
According to a company news release, wounds containing high concentrations of HA heal rapidly with little scarring. The effect is thought to be due to the molecule's ability to serve as a transportation system between the epidermal and dermal skin layers, allowing increased efficiency in the process of wound healing (inflammatory cell migration, fibroblast cell migration, cytokine migration, and epithelial cell migration).
The approval was based on the results of a study in 27 patients with 53 nonhealing ulcers of at least one month's duration (mean, 25.34 weeks). In the study, treatment was well tolerated and 89% of ulcers were healed at four months.
The HA-based gel was approved by the U.S. Food and Drug Administration, the Ecuadorian Ministry of Health, and the Panamanian Ministry of Health in April 2002, March 2005, and September 2005, respectively
charles wilson <profitablestock@yahoo.com> escribió:
UPDA closed .26 but in AH .288 run is inminent...news coming on monday and oil price climbing fast
__________________________________________________
Do You Yahoo!?
Tired of spam? Yahoo! Mail has the best spam protection around
http://mail.yahoo.com
[Non-text portions of this message have been removed]
--------------------------------------------------------------------------------
YAHOO! GROUPS LINKS
Visit your group "seriousdaytraders" on the web.
To unsubscribe from this group, send an email to:
seriousdaytraders-unsubscribe@yahoogroups.com
Your use of Yahoo! Groups is subject to the Yahoo! Terms of Service.
--------------------------------------------------------------------------------
By: mommasaid2
02 Mar 2006, 06:25 PM EST
Msg. 7783 of 7821
Jump to msg. #
FOUND THIS RUMOR ON ALLSTOCKS MSG BOARD :
Author Topic: XKEM - STAYING STRONG
Peaser01
Member
Member Rated:
posted March 02, 2006 13:41
--------------------------------------------------------------------------------
Rumour has it that Dr. Ramesh C. Pandey Ph.D., is getting back from Africa this weekend, look for a PR on Monday.
--------------------
Buy Low. Sell High.
Xkem ---- my pick 300% to win !
XKem ----- News out next week!
0.0120 -0.0110 dIPS SIZE ! rEADY TO RELOADED !
XKEm ----- good chance to pick up under 0.0120 !
Subscribe to Ad free and enjoy an ad-free experience
Try Now
Keep the Ads